Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK)
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...
USA Today5d
Arizona says GlaxoSmithKline's greed endangered kids with asthma
The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...
pharmaphorum3d
FDA clears GSK's Priorix, first new MMR vaccine in 50 years
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
CFRA cuts GlaxoSmithKline stock price target to $40, maintains hold
CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...
Deutsche Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
Detroit Free Press5d
Arizona says GlaxoSmithKline's greed endangered kids with asthma
Arizona sued drug manufacturer GlaxoSmithKline over what it calls deceptive practices involving the inhaled corticosteroid Flovent that endangered asthma patients. The lawsuit filed Thursday in ...